Report Library
All ReportsDiabetes CVOTs Primary Care KOL Interview
December 01, 2016
Biomedtracker and Datamonitor Healthcare interviewed a primary care physician (PCP) in the US to gauge the impact of Jardiance's
EMPA-REG and Victoza's LEADER cardiovascular outcomes trials (CVOT) in that important segment of the
Type 2 diabetes market.
The PCP discussed:
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
- What type of patients and lines of therapy the drugs would be used in for Type 2 diabetes
- Use of the particular drugs versus the overall SGLT-2 inhibitor and GLP-1 agonist classes and view on semaglutide
- Role of possible differing mechanisms for the CV benefit
- Impact of label changes
- Projections on use
- Implications for DPP-IV inhibitors
- Whether cardiologists would have a role in uptake
- Insurance coverage and impact of pay-for-performance
- Usage in diabetic nephropathy
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: |
Acute Coronary Syndrome (ACS)
Acute Decompensated Heart Failure - Reduced Ejection Fraction (Acute HFrEF) Atherosclerosis Cardiovascular Disease Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) Coronary Artery Disease Diabetes Mellitus, Type II Diabetic Nephropathy Ischemic Stroke |
Additional Resources: